Remove 2015 Remove Packaging Remove Pharmacy
article thumbnail

Analysis Life Sciences Thank You Ahead of a November deadline, FDA finalizes guidance on waivers, exemptions or exceptions from supply chain security requirements

Agency IQ

a wholesaler or pharmacy) would be able to see a valid chain of custody for a product. For example, as of January 1, 2015, manufacturers needed to have in place systems to comply with requirements related to the management of suspect and illegitimate products, verification requests, and the maintenance of an electronic database.

FDA 40
article thumbnail

The rising demand for lentiviral vectors for in vivo gene therapy

Drug Target Review

VIVEbiotech is involved in the manufacture of more than 50 different LVVs since 2015, eight of these programmes being for in vivo applications. Mainly, I would highlight the use of different pseudotypes, optimised packaging plasmids and modified cell lines to increase targeting of lentiviral vectors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Analysis Life Sciences Thank You The cost of artificially short expiration dates: Worsened shortages, higher costs and more waste

Agency IQ

In some cases, manufacturers have determined that specific drug products have limited stability when the original packaging is opened. For example, the stability of the oral anticoagulant Pradaxa (dabigatran; Boehringer Ingelheim) is compromised once the original packaging is opened due to concerns related to moisture.

Science 40
article thumbnail

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

Agency IQ

To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94 The rule, will also, if finalized, address communication with State boards of pharmacy. Read our analysis of that rule here and here. ]

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in December 2023

Agency IQ

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA 40
article thumbnail

FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus)

The Pharma Data

“Since 2015, BARDA has partnered with Regeneron to develop a life-saving treatment for Ebola Zaire. Regeneron is actively working with non-governmental organizations and public health agencies to ensure continued access to Inmazeb in low- and middle-income countries.